Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study - PubMed (original) (raw)
Clinical Trial
. 2013 Mar;27(3):e376-83.
doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3.
Affiliations
- PMID: 23030767
- DOI: 10.1111/j.1468-3083.2012.04716.x
Clinical Trial
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
K A Papp et al. J Eur Acad Dermatol Venereol. 2013 Mar.
Abstract
Background: Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production.
Objective: Assess apremilast efficacy and safety in moderate to severe plaque psoriasis.
Methods: Phase II, 12-week, multicenter, double-blind, placebo-controlled, parallel-group, dose-comparison study of 259 subjects randomized 1 : 1 : 1 to placebo, apremilast 20 mg QD or apremilast 20 mg BID.
Results: More subjects receiving apremilast 20 mg BID achieved ≥ 75% reduction in Psoriasis Area and Severity Index (PASI-75) vs. placebo (24.4% vs. 10.3%; P = 0.023). A similar proportion of subjects receiving apremilast 20 mg QD and placebo achieved PASI-75 at week 12 [9/87 (10.3%, each group)]. Mean per cent reduction in PASI from baseline was 17.4% for placebo, 30.3% for apremilast 20 mg QD (P = 0.021 vs. placebo) and 52.1% for apremilast 20 mg BID (P < 0.001). Apremilast 20 mg BID significantly decreased mean body surface area involvement vs. placebo (30.8% vs. 3.2%; P < 0.001). The most common adverse events were headache, nasopharyngitis, diarrhoea and nausea. Most events (> 90%) were mild to moderate and did not lead to study discontinuation. Serious adverse events occurred in four placebo subjects (panic attack, hospitalization for rehabilitation, hospitalization for alcoholism, worsening psoriasis), one receiving apremilast 20 mg QD (knee surgery) and in one receiving apremilast 20 mg BID (worsening psoriasis). The panic attack was considered treatment-related; both cases of worsening psoriasis occurred after medication discontinuation. No deaths or opportunistic infections were reported.
Conclusion: Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis.
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.
Similar articles
- The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. Reich K, et al. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19. J Eur Acad Dermatol Venereol. 2017. PMID: 27768242 Free PMC article. Clinical Trial. - Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Papp K, et al. Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29. Lancet. 2012. PMID: 22748702 Clinical Trial. - Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O. Ohtsuki M, et al. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. J Dermatol. 2017. PMID: 28391657 Free PMC article. Clinical Trial. - Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Armstrong AW, et al. J Am Acad Dermatol. 2016 Oct;75(4):740-746. doi: 10.1016/j.jaad.2016.05.040. Epub 2016 Jul 28. J Am Acad Dermatol. 2016. PMID: 27476973 Review. - Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A. Bianchi L, et al. Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1121-8. doi: 10.1080/17425255.2016.1206886. Epub 2016 Jul 14. Expert Opin Drug Metab Toxicol. 2016. PMID: 27376729 Review.
Cited by
- Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
Crowley EL, Gooderham MJ. Crowley EL, et al. Pharmaceutics. 2023 Dec 22;16(1):23. doi: 10.3390/pharmaceutics16010023. Pharmaceutics. 2023. PMID: 38258034 Free PMC article. Review. - The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update.
Çetinarslan T, Kümper L, Fölster-Holst R. Çetinarslan T, et al. Front Mol Biosci. 2023 Aug 16;10:1159404. doi: 10.3389/fmolb.2023.1159404. eCollection 2023. Front Mol Biosci. 2023. PMID: 37654796 Free PMC article. Review. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review. - Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
Xu Y, Li Z, Wu S, Guo L, Jiang X. Xu Y, et al. Front Immunol. 2023 Jun 2;14:1180170. doi: 10.3389/fimmu.2023.1180170. eCollection 2023. Front Immunol. 2023. PMID: 37334353 Free PMC article. - Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies.
Liu Y, Li Y, Du H. Liu Y, et al. Postepy Dermatol Alergol. 2023 Feb;40(1):165-170. doi: 10.5114/ada.2022.119081. Epub 2022 Sep 6. Postepy Dermatol Alergol. 2023. PMID: 36909912 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical